| Detected | Trial | Change |
|---|---|---|
| 2026-08-15 | NCT07543536 Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer · Sun Yat-sen University |
Recruitment opened |
| 2026-08-09 | NCT07616427 Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted… · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-09 | NCT07616440 Pilot Study on the Clinical Efficacy of Focused Ultrasound-Mediated Targeted Drug… · Second Affiliated Hospital, School of Medicine, Zhejiang University |
Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine |
| 2026-08-06 | NCT07413939 RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People… · Hoffmann-La Roche |
Trial sites expanded: 109 -> 152 locations |
| 2026-08-06 | NCT06876714 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+… · Alliance for Clinical Trials in Oncology |
Trial sites expanded: 671 -> 684 locations |
| 2026-08-02 | NCT06479460 Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive… · The First Affiliated Hospital with Nanjing Medical University |
overall status: Recruiting → Unknown |
| 2026-07-31 | NCT07196774 A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in… · Jiangsu HengRui Medicine Co., Ltd. |
Enrollment closed, study ongoing |
| 2026-07-30 | NCT06445400 A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients… · Sichuan Baili Pharmaceutical Co., Ltd. |
date change Primary completion moved earlier: 2026-12 -> 2025-07-21 |
| 2026-07-24 | NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or… · Sichuan Baili Pharmaceutical Co., Ltd. |
date change Primary completion pushed: 2026-05 -> 2026-10 |
| 2026-07-24 | NCT06316531 A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or… · Sichuan Baili Pharmaceutical Co., Ltd. |
date change Completion pushed: 2026-05 -> 2028-12 |
| 2026-07-24 | NCT03975647 A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1)… · Seagen, a wholly owned subsidiary of Pfizer |
Trial sites expanded: 486 -> 490 locations |
| 2026-07-23 | NCT07136428 Asciminib in HER2+ Breast Cancer Brain Metastases · Duke University |
Recruitment opened |
| 2026-07-21 | NCT04360941 PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · Royal Marsden NHS Foundation Trust |
date change Primary completion pushed: 2026-07-31 -> 2027-07-31 |
| 2026-07-21 | NCT04360941 PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer · Royal Marsden NHS Foundation Trust |
date change Completion pushed: 2026-07-31 -> 2027-07-31 |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-14 | NCT07766772 Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine… | Fujian Cancer Hospital NEW | Phase 2 |
| 2026-08-05 | NCT07748260 De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast | Guangdong Provincial People's Hospital NEW | Phase 3 |
| 2026-08-05 | NCT07748598 HER2+ CNS Surveillance | The Clatterbridge Cancer Centre NHS Foundation Trust NEW | |
| 2026-07-31 | NCT07739511 Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A… | Liu Shu NEW | Phase 1/2 |
| 2026-07-24 | NCT07726342 SMP-656 for HER2-Positive Advanced Breast Cancer | Chengdu SciMount Pharmatech Co., Ltd. NEW | Phase 2 |
| 2026-07-15 | NCT07706179 Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast… | University of Wisconsin, Madison NEW | Phase 2 |
| 2026-07-10 | NCT07695259 Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer | Wen-Ming Cao NEW | Phase 4 |
| 2026-06-29 | NCT07673029 A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or… | GeneQuantum Healthcare (Suzhou) Co., Ltd. NEW | Phase 3 |
| 2026-06-15 | NCT07647263 Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast… | The First Affiliated Hospital of Soochow University NEW | Phase 2 |
| 2026-05-28 | NCT07612215 Elacestrant in Advanced Triple Positive Breast Cancer | NYU Langone Health NEW | Phase 1/2 |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment… | Hebei Medical University Fourth Hospital | Recruiting |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with… | The First Hospital of Jilin University | Not Yet Recruiting |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | The First Affiliated Hospital with Nanjing Medical University | Not Yet Recruiting |
| Phase 3 | |||
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast… | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting |
| NCT06846437 | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Shanghai JMT-Bio Inc. | Recruiting |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | Dr Rajendra A. Badwe | Recruiting |
| NCT06992882 | A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral… | Fudan University | Recruiting |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth… | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in… | Jazz Pharmaceuticals | Recruiting |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in… | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal… | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable… | Shanghai JMT-Bio Inc. | Recruiting |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting |
| NCT07673029 | A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or… | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Recruiting |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+… | Alliance for Clinical Trials in Oncology | Recruiting |
| NCT07543536 | Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer | Sun Yat-sen University | Recruiting |
| NCT05388500 | Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C) | Institut de cancérologie Strasbourg Europe | Not Yet Recruiting |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | Institut de cancérologie Strasbourg Europe | Not Yet Recruiting |
| NCT05346224 | A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant… | Shanghai Henlius Biotech | Active, Not Recruiting |
| NCT06265428 | A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer | DualityBio Inc. | Active, Not Recruiting |
| NCT07239271 | A Multicenter Phase III Clinical Study and Translational Research on Adaptive Neoadjuvant… | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not Yet Recruiting |
| NCT05705401 | Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for… | NRG Oncology | Active, Not Recruiting |
| NCT06968585 | A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive… | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active, Not Recruiting |
| NCT04208178 | Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance… | Novartis Pharmaceuticals | Active, Not Recruiting |